The study will test a medication called cemiplimab (also known as LIBTAYO), which is given through an intravenous infusion. This medicine belongs to a group of drugs called immunotherapy, which helps the body’s immune system fight cancer cells. The purpose is to determine if giving cemiplimab after surgery can help prevent the cancer from returning, compared to patients who receive no additional treatment after surgery.

During the study, participants will either receive cemiplimab treatment or be observed without treatment. The medication will be given through an infusion into a vein every few weeks. The total treatment period may last up to 42 weeks. Doctors will monitor the participants’ health and check if the cancer returns during and after the treatment period.

The purpose of this study is to determine how effective the combination of these medications is at eliminating cancer cells before surgery. The treatment is given in two phases – before surgery (called neoadjuvant treatment) and after surgery (called adjuvant treatment). Before surgery, patients receive both medications. After surgery, all patients receive zimberelimab, and some patients may also continue receiving sacituzumab govitecan.

During the study, patients will receive regular medical examinations and various tests to monitor their health and how well the treatment is working. The treatment period may last up to 54 weeks. Zimberelimab is given at doses up to 360 milligrams, while sacituzumab govitecan is given based on the patient’s body weight, up to 10 milligrams per kilogram of body weight.

The purpose of this study is to compare how well MK-2870 combined with pembrolizumab works compared to pembrolizumab alone in preventing the cancer from coming back after surgery. Before being assigned to one of these treatment groups, participants will first receive pembrolizumab along with platinum-based chemotherapy before surgery, which is called neoadjuvant treatment. After surgery, if cancer cells are still found in the removed tissue, meaning a complete response was not achieved, participants will then be randomly assigned to receive either MK-2870 plus pembrolizumab or pembrolizumab alone as adjuvant treatment, which means treatment given after surgery to reduce the risk of cancer returning.

During the study, participants will have regular check-ups that include imaging scans such as computed tomography or magnetic resonance imaging to monitor for any signs of cancer returning. The study will measure how long participants remain free of disease, how long they survive overall, and whether the cancer spreads to distant parts of the body. Researchers will also assess quality of life and monitor for any side effects throughout the treatment period. The treatment period can last up to several months, and participants will continue to be followed for a number of years to track long-term outcomes.

Participants in the study will receive the treatments through an intravenous infusion, which means the medicine is given directly into a vein. The study will take place over a period of up to 12 months. During this time, doctors will monitor the patients to see how the cancer responds to the treatment and to check for any side effects. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

The study aims to find out if the treatments can help achieve a complete response, meaning no cancer cells are found after surgery. It will also look at how long patients remain free of cancer after treatment and surgery. The results will help determine if these treatments can be a safe and effective option for people with early-stage .

Participants in the study will receive treatments through an intravenous infusion, which means the medication is given directly into a vein. The medications used in the study include cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, which are all types of chemotherapy drugs. These drugs work by targeting and killing cancer cells. The study will also use durvalumab, an immunotherapy drug that helps the immune system recognize and attack cancer cells.

The study will take place over a period of time, with participants receiving treatment for up to 16 weeks. The goal is to determine if adding durvalumab after the initial treatment can help prevent the cancer from returning. Participants will be monitored throughout the study to assess their response to the treatment and any side effects they may experience. The study is designed to provide valuable information on improving treatment outcomes for patients with early-stage NSCLC.

The purpose of the study is to evaluate the effectiveness and safety of these treatments when given before and after surgery. The study will follow a course where patients receive the treatments before surgery to shrink the tumor, known as neoadjuvant treatment, and then continue with additional treatments after surgery, known as adjuvant treatment. The study aims to see how well these treatments work in reducing the cancer and how safe they are for patients.

Participants in the study will receive either the active medications or a placebo. The study will monitor the response of the cancer to the treatments, as well as any side effects experienced by the participants. The goal is to gather information that could help improve treatment options for patients with early-stage NSCLC that can be surgically removed.

Participants in the study will be randomly assigned to one of two groups. One group will receive Ociperlimab in combination with Tislelizumab, while the other group will receive Pembrolizumab followed by a placebo. The treatments are given as infusions, which means they are administered directly into the bloodstream through a vein. The study will monitor the participants over a period of time to assess the effectiveness of the treatments in improving survival rates.

The trial aims to provide valuable information on how these treatments can help patients with non-small cell lung cancer. By comparing the different treatment options, researchers hope to find the most effective approach for managing this type of cancer. The study will also look at the quality of life of participants and any side effects they may experience during the trial.

The study is designed to compare two groups of patients: those who receive the chemotherapy treatment and those who do not, to see if the treatment helps in extending the time patients remain free from cancer. The chemotherapy treatment is given in cycles, with each cycle lasting a few weeks, and the total treatment period can last up to 16 weeks. The study aims to personalize patient care by using a special test called the 14-Gene Prognostic Assay, which helps determine the risk level of cancer returning based on the genetic makeup of the tumor.

Participants in the study will be monitored over time to track their health and any signs of cancer returning. The study will help researchers understand if using chemotherapy after surgery can improve outcomes for patients with high or intermediate risk of cancer recurrence. This information could lead to better treatment strategies for patients with early-stage non-squamous NSCLC in the future.

The purpose of the study is to evaluate how well the combination of Tiragolumab and Atezolizumab works in preventing the return of cancer in patients whose tumors have a specific protein called PD-L1. The study will also look at the safety of these medications and how they affect the quality of life of the participants. Participants will receive the treatment over a period of up to 12 months, and their health will be monitored regularly to assess the effects of the treatment.

Throughout the study, researchers will collect information on how long participants remain free of cancer, any side effects they experience, and their overall survival. The study will also measure the levels of Tiragolumab and Atezolizumab in the blood at different times to understand how the body processes these medications. This trial aims to provide valuable insights into the potential benefits of combining Tiragolumab with Atezolizumab for treating NSCLC.

The purpose of the study is to determine how well osimertinib works in keeping the cancer from coming back, which is referred to as disease-free survival. Participants in the study will be randomly assigned to receive either osimertinib or a placebo. The study will be conducted in a way that neither the participants nor the researchers know who is receiving the actual medication or the placebo, a method known as double-blind. This helps ensure that the results are not influenced by expectations about the treatment.

Throughout the study, participants will be monitored for several years to assess the long-term effects of the treatment. This includes regular check-ups and tests to track their health and any changes in their condition. The study will also look at overall survival rates and the quality of life of the participants, using questionnaires and other assessments. The safety of the treatment will be closely watched by checking for any side effects or health changes during the study period.

The purpose of this study is to evaluate the safety and effectiveness of the treatment combinations in patients with unresectable NSCLC. Participants in the study will be randomly assigned to receive either the combination of SBRT and pembrolizumab or SBRT and a placebo. The study will monitor participants over a period to assess how long they remain free from events such as cancer progression or recurrence, which is referred to as Event-Free Survival (EFS). Additionally, the study will look at overall survival rates and other health outcomes related to quality of life and side effects.

Throughout the study, participants will undergo regular health assessments to track their response to the treatment and any side effects they may experience. The trial aims to provide valuable information on whether adding pembrolizumab to SBRT can improve outcomes for patients with early-stage NSCLC who cannot undergo surgery. The study is expected to continue until 2026, with ongoing evaluations to ensure the safety and well-being of all participants.